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Objective: Sitagliptin, a dipeptidyl peptidase IV (DPP-Ⅳ) inhibitor, has a biological role in improving the
serum levels of glucagon-like peptide 1 (GLP-1). Hence, we sought to determine the effect of sitagliptin
on myocardial inﬂammation, collagen metabolism, lipid content and myocardial apoptosis in diabetic
rats.
Materials and methods: The type 2 diabetic rat model was induced by low-dose streptozotocin and a
high-fat diet. Characteristics of diabetic rats were evaluated by electrocardiography, echocardiography
and blood analysis. Cardiac inﬂammation, ﬁbrosis, cardiomyocyte density, lipid accumulation, and
receptor-interacting protein kinase 3 (RIP3) level, related to apoptosis, were detected by histopathologic
analysis, RT-PCR and western blot analysis to evaluate the effects of sitagliptin on myocardial remodeling
of the left ventricle.
Results: Diabetic rats showed myocardial hypertrophy or apoptosis, inﬂammation, lipid accumulation,
myocardial ﬁbrosis, elevated collagen content, RIP3 overexpression, and left-ventricular dysfunction.
Sitagliptin could reverse the overexpression of RIP3 and alleviate cellular apoptosis in myocardial tissues.
It could signiﬁcantly improve left-ventricular systolic pressure and þdp/dt max, reduce the E/E0 ratio, left
ventricular end diastolic pressure, dp/dt max and Tau in diabetic rats.
Conclusions: Sitagliptin might have a myocardial protective effect by inhibiting apoptosis, inﬂammation,
lipid accumulation and myocardial ﬁbrosis in diabetic rats, for a potential role in improving left-
ventricular function in diabetes.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Accumulating evidence indicates that diabetic cardiomyopathy
(1,2) is a disorder of myocardial lesions induced by high glucose. It
features myocardial hypertrophy or apoptosis (3), inﬂammation,
lipid accumulation, and myocardial ﬁbrosis (4). As well, it might
feature systolic and/or diastolic dysfunction of the heart and7, Jinan, Shandong Province,
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Production and hosting by Elsevieincreased mortality (5). Sari et al. (6) declared that cardiac endo-
plasmic reticulum stress (ERS) and ERS-initiated apoptosis were
involved in diabetes. Receptor-interacting protein 3 (RIP3), an
important signal molecule, is involved in tumor necrosis factor a
(TNF-a)-mediated apoptosis and related to mitochondrial energy
metabolism (7,8), but its expression in the diabetic heart is not
known.
Sitagliptin is a dipeptidyl peptidase IV (DPP-Ⅳ) inhibitor and
has a role in improving the activity of glucagon-like peptide-1
(GLP-1) (9), an incretin hormone secreted from the distal intes-
tine L cells with glucose-dependent release that promotes the
secretion of postprandial insulin (10). GLP-1 receptors (GLP-1Rs)
exist widely in islets, myocardium and brain tissue. Relatively
low GLP-1 concentrations as compared with in vivo blood con-
centrations promoted insulin secretion independent of the
cAMP-protein kinase A pathway (11). With decreased activity ofr B.V. All rights reserved.
Y.-S. Liu et al. / Journal of Pharmacological Sciences 127 (2015) 260e274 261GLP-1 in diabetic patients, endogenous GLP-1 could be dissolved
rapidly by DPP-Ⅳ (12).
Sitagliptin could prevent GLP-1 degradation in the short term,
elevate serum levels of GLP-1 and enhance or delay the release of
insulin, to lower blood glucose (13,14). Furthermore, recent reports
demonstrated that GLP-1 has a key role in the inhibiting apoptosis
during ischemia-reperfusion (I/R) injury and improved cardiac
function (15).
Hence, we evaluated the effect of sitagliptin on inﬂammation,
collagen metabolism, lipid content, myocardial apoptosis (RIP3
expression) and cardiac function in diabetic rats to detect additional
beneﬁts for sitagliptin beyond its blood glucose-lowering effect.
2. Materials and methods
2.1. Animals and supplementation
We purchased 70 male, 8-week-old Wistar rats (120e140 g)
from the experimental animal center of Shandong University
(Jinan, China). All experimental procedures were performed in
accordance with animal protocols approved by the Shandong
University Animal Care Committee. Rats were housed at 22 C with
12-h light/dark cycles. All mice were fed a high-fat diet (34.5% fat,
17.5% protein, 48% carbohydrate; Beijing HFK Bio-Technology). Four
weeks later, the intraperitoneal glucose tolerance test (IPGTT) and
intraperitoneal insulin tolerance test (IPITT) were performed and
blood was sampled by the jugular vein. Fasting insulin and fasting
blood glucose (FBG) were measured, and the insulin sensitivity
index [ISI ¼ ln (FBG  fasting insulin)1] was calculated. Control
rats received citrate buffer (intraperitoneally) alone and rats with
insulin resistance received a single intraperitoneal injection of STZ
(Sigma, St. Louis, MO; 30 mg/kg intraperitoneally in 0.1 mol/L cit-
rate buffer, pH 4.5) as described (16). At one week after STZ
administration, rats with FBG > 11.1 mmol/L in 2 consecutive ana-
lyses were considered the diabetic model. Animals were then
randomized to one of 2 groups for treatment: control rats (n ¼ 10),
normal chow; or diabetes rats, induced with DPP-Ⅳ inhibitor (low-
dosage sitagliptin, 30 mg/kg/d) (n ¼ 20) [DPP-IVi (Low)] and (high-
dosage sitagliptin, 50 mg/kg/d) (n ¼ 20) [DPP-IVi (High)]. Treat-
ment with sitagliptin started 4 weeks after STZ injection. The rats
were killed after 17 weeks of diabetes.
2.2. Blood analyses
Blood was collected from the jugular vein after rats fasted for
8 h. FBG and circulating levels of cholesterol, triglycerides, low-
density lipoprotein (LDL) and high-density lipoprotein (HDL)
were analyzed with use of the Bayer blood chemistry analyzer
(Bayer, Tarrytown, NY). Free fatty acid (FFA) concentrations were
measured by use of an enzymatic test kit (CSB-E08770r; HuaMei
BIO-TECH, Wuhan, China). ISI was calculated. Plasma insulin levels
were measured by use of the rat insulin ELISA kit based on the
direct Sandwich ELISA technique (Mercodia AB, Sweden). Hemo-
globin A1C (HbA1c) level was measured by the Nycocard Reader
(Ranbaxy, India).
2.3. Electrocardiography and echocardiography
ECG was recorded with the limb leads (I, II, III, aVR, aVL, aVF) to
evaluate cardiac electrical activity. Echocardiography involved use
of the Philips IE33 imaging system (S12-4). Images were obtained
from 2D, M-mode, pulsed-wave Doppler and tissue Doppler im-
aging (TDI). All measurements were performed by the same
researcher and were averaged from 6 consecutive cardiac cycles.
Wall thickness and LV dimensions, including LV end systolicdiameter (LVEDs) and LV end diastolic diameter (LVEDd), were
obtained from the long-axis view. LV ejection fraction (LVEF) and
fractional shortening (FS) were measured according to American
Society of Echocardiography guidelines (16,17). The mitral-valve
pulsed Doppler recordings were obtained from the apical four-
chamber view. After pulsed Doppler, transmitral ﬂow velocity
variables, including peak E, peak A, and E/A ratio were evaluated
(the early (E0) and late (A0) diastolic velocity were analyzed and E0/
A0 and E/E0 values were calculated) and tissue Doppler imaging of
the mitral annulus was obtained from the apical four-chamber
view.
2.4. Hemodynamics by Millar catheter
Rats were anesthetized with urethane (1 g/kg), then the right
carotid artery was cannulated and a transducer was advanced into
the left ventricle to measure the rate of pressure changes (±dp/dt
max), blood pressure, and heart rate with a microtip pressure
transducer (Millar Instruments) and LVED pressure (LVEDP) was
measured. Tau was calculated with the LV time constant Tau ¼ P/
(dp/dt).
2.5. Morphometric analysis
Heart tissues were ﬁxed in 10% formalin, embedded in parafﬁn,
and sectioned at 5-mm thick. A single myocyte was measured with
images captured from H&E-stained sections. The myocyte cross-
sectional area was assessed by 400 magniﬁcation within the LV,
and a mean was obtained by quantitative morphometry with
automated image analysis (Image-Pro Plus 5.0; Media Cybernatics,
Houston, TX).
Dark greenestained collagen ﬁbers were quantiﬁed to measure
ﬁbrosis in Masson trichrome-stained sections. The collagen volume
fraction (CVF) and perivascular collagen area to luminal area (PVCA/
LA) were analyzed by quantitative morphometry with automated
image analysis (Image-Pro Plus 5.0). CVF was calculated as reported
previously (18). Perivascular collagen was excluded from the CVF
measurement. To normalize the PVCA around vessels with different
sizes, perivascular collagen content was represented as the PVCA/
LA ratio. Interstitial and perivascular ﬁbrosis was evaluated by
Picrosirius red staining. Sections were stained with 0.5% sirius red
(Sigma) in saturated picric acid for 25 min. Collagen was stained
red. Myocardial frozen sections (5 mm) were stained with Oil-red O
(Sigma) for 10 min, washed, then counterstained with hematoxylin
for 30 s. A Nikon microscope (Nikon, Melville, NY) was used to
capture images.
An in situ cell death detection kit (Roche GmBH, Germany) was
used for TUNEL assay. Brieﬂy, slides were deparafﬁnized, rehy-
drated with xylene; underwent a graded ethanol series; and were
permeablized with hot 0.1 M citrate buffer, pH 6.0; incubated with
reaction mixture containing TdT; and labeled with dUTP for 1 h at
37 C. Images were captured by confocal laser scanning microscopy
(Zeiss LSM510). For a negative control, TdT was omitted from the
reaction mixture.
2.6. Immunohistochemical staining
Parafﬁn sections underwent immunohistochemistry by a
microwave-based antigen retrieval method. Sections were incu-
bated with primary antibodies for rabbit polyclonal collagen I and
III, tumor necrosis factor TNF-a, and interleukin 6 (IL-6) (Abcam,
Cambridge, MA) overnight, then with biotinylated secondary anti-
body for 30 min at 37 C. Negative controls were omission of the
primary antibody. Stained sections were developed with dia-
minobenzidine and counterstained with hematoxylin. Sections
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scope (Olympus, Japan).
2.7. RT-PCR
Total RNA was prepared with the TRIzol reagent (Gibco/Invi-
trogen, Carlsbad, CA). RT-PCR involved the primer sequences forFig. 1. Blood analysis demonstrating metabolic disturbance. A. FBG: fasting blood glucose, BG
index; B. TC: Total cholesterol levels, TG: triglyceride levels, HDL-C: high density lipoprote in-
serum levels of GLP-1 and serum levels of GLP-1 at 30 min after oral glucose testing. D and E
(IPITT) ﬁndings. (Data are mean ± SEM; n ¼ 7e10 per group. Compared with the control g
Compared with DPP-Ⅳi (Low), xP ＜ 0.05, xxP ＜ 0.01.).RIP3, forward 50-ACC ACTGAGCGAGCATCCTTCC-30 and reverse 50-
CCCGGAACACGGCTCCGAAC-30; and b-actin, forward 50-AGA CCT
TCA ACA CCC CAG-30 and reverse 50-CAC GAT TTC CCT CTC AGC-
30. Reactions were carried out on a real-time PCR thermocycler
(IQ5 Real-Time PCR cycler; Bio-Rad), with SYBR green as ﬂuo-
rescence dye. Relative expression analysis involved the 2△△CT
method.at 10:00 am; HbA1c: Glycated hemoglobin, FINS: Fasting insulin, ISI: insulin sensitivity
cholesterol, LDL-C: low density lipoprotein-cholesterol, FFAs: free fatty acids; C. Fasting
. intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin tolerance test
roup, *P ＜ 0.05, **P ＜ 0.01; Compared with DPP-Ⅳi (High), #P ＜ 0.05, ##P ＜ 0.01;
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Western blot analysis was performed as described previously
(19) with antibodies for RIP3 (Calbiochem, La Jolla, CA), collagen I
and III, TNF-a and IL-6 (Abcam), followed by anti-IgG horseradish
peroxidaseeconjugated secondary antibody. Protein levels were
normalized to that of b-actin as an internal control and phospho-
speciﬁc proteins to that of total protein.2.9. Statistical analysis
Data are presented as mean ± SD for continuous variables or
proportions. After testing for normal distribution of variables, dataFig. 2. Electrocardiography and cardiac function measured by echocardiography and Millar c
C: diabetic rats with DPP-Ⅳi (High); 2.2 A1: 4D echocardiograms, A2: 2D echocardiograms b
A5: tissue Doppler echocardiograms. BeG: Sequential evaluations of left ventricular end dias
and LVEDP, DeF: Representative þdp/dt and dp/dt, and G: Tau. (Data are mean ± SEM; n ¼
(High), #P ＜ 0.05, ##P ＜ 0.01; Compared with DPP-Ⅳi (Low), xP ＜ 0.05, xxP ＜ 0.01.).were analyzed by Student's two-tail t test and one-way ANOVA
followed by post-hoc least signiﬁcant difference test as appropriate.
Correlation was assessed by Pearson or Spearman rank order cor-
relation test, as appropriate. Statistical analyses involved use of
SPSS 16.0 (SPSS, Chicago, IL, USA). A two-tailed P < 0.05 was
considered statistically signiﬁcant.3. Results
3.1. Baseline characteristics of diabetic rats
Diabetic rats showed polydipsia, polyphagia, and polyuria as
compared with other rats (P < 0.01). As compared with the controlatheter. 2.1 Electrocardiogram A: control group, B: diabetic rats with DPP-Ⅳi (Low), and
y short-axis side, A3: M-mode, A4: pulse Doppler echocardiograms of mitral inﬂow, and
tolic diameter (LVEDD) (B), FS (C), LVEF (D), E/A (E), E0/A0 (F) and E/E0 (G); 2.3 AeC: LVSP
7e10 per group. Compared with control, *P＜ 0.05, **P＜ 0.01; Compared with DPP-Ⅳi
Fig. 2. (continued).
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(P < 0.01e0.05) and heart rate and increased blood pressure
(P < 0.01e0.05); however, with sitagliptin treatment, body weight
increased and heart rate and blood pressure decreased
(P < 0.01e0.05).
3.2. Sitagliptin improved blood glucose and lipid metabolism
Insulin resistance appeared after 4 weeks with a high-fat diet.
One week after STZ injection, FBG increased markedly indiabetic rats. Diabetic rats showed insulin resistance, moderate
hyperglycemia, hyperlipidemia, and decreased ISI (P < 0.05)
(Fig. 1A). Serum levels of total cholesterol, total triglycerides,
LDL-C, and FFA were higher for diabetic rats than controls
(P < 0.05) and decreased with sitagliptin treatment
(P < 0.01e0.05) (Fig. 1B). Plasma GLP-1 decreased under both
fasting and 30 min after oral glucose (P < 0.01e0.05) and
increased with sitagliptin treatment (P < 0.01e0.05) in diabetic
rats (Fig. 1C). Sitagliptin had no effect on IPGTT and IPITT results
(Fig. 1D and E).
Fig. 3. Pathology features of the diabetic hearts. A1: Heart size; A2: cross sections of hearts at the papillary muscle level; A3: Longitudinal sections of LV stained with hematoxylin
and eosin (H&E). A4: Transverse sections of LV stained with H&E. Quantitative data of B: heart weight to body weight (HW/BW) ratio and C: myocyte size. (Data are mean ± SEM;
Compared with control, *P ＜ 0.05, **P ＜ 0.01; Compared with DPP-Ⅳi (High), #P ＜ 0.05, ##P ＜ 0.01; Compared with DPP-Ⅳi (Low), xP ＜ 0.05, xxP ＜ 0.01.).
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Control rats showed P waves, T waves and amplitude consis-
tency of QRS waves (Fig. 2.1). For diabetic rats, 66.7% showed
abnormal ECG results, and QRS “electrical alternans” phenomena
were slightly more common than in controls rats, with super-
ventricular tachycardia, ventricular tachycardia, slow heart rate and
other complex arrhythmia in diabetic rats. However, with sita-
gliptin treatment, for diabetic rats, 42.4% showed abnormal ECG
results, with no complex arrhythmia.
3.4. Sitagliptin improved LV structure and function
At the beginning, the size of LV chambers, LVIDs and LVIDd did
not differ in control and diabetic rats (P > 0.05); however, at theend, compared with controls, diabetic rats showed increased LVIDs
and LVIDd (P < 0.05) (Fig. 2.2). Sitagliptin treatment decreased
LVIDs and LVIDd (P < 0.05).
At the beginning, control and diabetic rats showed no diastolic
or systolic dysfunction (P > 0.05). However, at the end, compared
with controls, diabetic rats showed decreased LVEF and FS
(P < 0.01e0.05), which was increased with sitagliptin treatment
(P < 0.01e0.05) (Fig. 2.2). Compared with controls, from 13 to 21
weeks, E/A, E0/A0 decreased (P < 0.01e0.05) and E/E0 increased
(P < 0.01e0.05) in diabetic rats, which was reversed with sitagliptin
treatment (Fig. 2.2).
Compared with controls, diabetic rats showed decreased LVSP
(P < 0.01) and ±dp/dt max (P < 0.01e0.05) and increased
LVEDP (P < 0.01); however, sitagliptin reversed these ﬁndings
(Fig. 2.3).
Fig. 4. Expression of glucagon-like peptide 1 (GLP-1) and receptors in the heart. Expression of A: GLP-1 and B: GLP-1 receptor. (Data are mean ± SEM; Compared with control,
*P ＜ 0.05, **P ＜ 0.01; Compared with DPP-Ⅳi (High), #P ＜ 0.05, ##P ＜ 0.01; Compared with DPP-Ⅳi (Low), xP ＜ 0.05, xxP ＜ 0.01.).
Fig. 5. DPP-Ⅳ inhibitor sitagliptin alleviated cardiac ﬁbrosis in diabetic rats. A1: Masson trichrome staining (collagen is blue and myocardium red) and Picrosirius red staining-
collagen ﬁbers stained bright red; bright-ﬁeld (A2), dark-ﬁeld (A3) show myocardial interstitial ﬁbrosis. A4eA5: Picrosirius red staining-bright-ﬁeld (A4), dark-ﬁeld (A5) show
perivascular ﬁbrosis. Quantitative analysis of B: CVF, C: collagen content by hydroxyproline assay, and D: perivascular collagen area to luminal area (PVCA/LA). (Data are
mean ± SEM; Compared with control, *P ＜ 0.05, **P ＜ 0.01; Compared with DPP-Ⅳi (High), #P ＜ 0.05, ##P ＜ 0.01; Compared with DPP-Ⅳi (Low), xP ＜ 0.05, xxP ＜ 0.01.).
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cardiomyocytes
Compared to controls, diabetic rats showed larger heart sizes,
higher ratio of heart weight to body weight (HW/BW) (P < 0.05)
(Fig. 3A), and increased myocardial hypertrophy and cellular cross-
sectional area (498.37 ± 14.31 vs 347.84 ± 12.27 mM3, P < 0.01)
(Fig. 3AeC). Diabetic rats also showed myocardial cell hypertro-
phy, muscle ﬁber derangement or fracture, irregular shape, and
uneven size of nuclei. Sitagliptin treatment reversed these
ﬁndings.
3.6. Sitagliptin increased GLP-1 content and downregulated the
density of GLP-1 receptors in diabetic hearts
As compared with controls, diabetic myocardial tissue showed
decreased GLP-1 content (P < 0.01) (Fig. 4A) and expression of GLP-Fig. 6. Sitagliptin reversed collagen, collagen degrading enzyme, inﬂammation and the fa
degrading enzyme MMP-1 and -9; 6.3: TNF-a and IL-6; and 6.4: fatty content in myocard
**P ＜ 0.01; Compared with DPP-Ⅳi (High), #P ＜ 0.05, ##P ＜ 0.01; Compared with DPP-Ⅳ1 receptor (GLP-1R) (P < 0.01) (Fig. 4B), which were reversed with
sitagliptin treatment (P < 0.01).
3.7. Sitagliptin alleviated cardiac ﬁbrosis in diabetic rats
The diabetic heart showed cardiac ﬁbrosis, with a diffuse,
small, patchy, and nonuniform pattern, as well as destroyed and
disorganized collagen network structure in the interstitial areas
(Fig. 5A1eA3) and perivascular areas (Fig. 5A4eA5). CVF
(4.8 ± 0.49 vs 0.47 ± 0.06, P < 0.01e0.05) and collagen content
(15.8 6 ± 0.43 vs 7.06 ± 0.31 mg/mg, P < 0.01) were higher in
diabetic rats than controls (Fig. 5B and C), and perivascular
collagen area/lumen area ratio (PVCA/LA) was increased
(2.74 ± 0.37 vs 0.5 ± 0.02, P < 0.01e0.05) (Fig. 5D). Compared with
controls, diabetic rats showed increased expression of collagen I
and III (Fig. 6.1). These ﬁndings were reversed with sitagliptin
treatment.tty content in diabetic heart. Sitagliptin reversed 6.1 collagen Ⅰ and Ⅲ; 6.2: collagen
ial and epicardial tissues. (Data are mean ± SEM; Compared with control, *P ＜ 0.05,
i (Low), xP ＜ 0.05, xxP ＜ 0.01.).
Fig. 6. (continued).
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TNF-a and IL-6 in diabetic hearts
Compared with controls, diabetic rats showed increased
expression of MMP-1 and -9 and TNF-a and IL-6 (Fig. 6.2 and 6.3),
which was decreased with sitagliptin treatment.3.9. Sitagliptin reduced lipid accumulation in myocardial and
epicardial tissue in diabetic hearts
The accumulation of triglycerides caused myocardial fatty
degeneration in diabetic rats, with increased staining in myocardial
tissue (7.03 ± 0.31 vs 0.32 ± 0.01, P < 0.01) (Fig. 6.4) and epicardial
adipose tissue (12.76 ± 0.48 vs 0.32 ± 0.01, P < 0.01), which was
reduced with sitagliptin treatment (P < 0.01e0.05).3.10. Sitagliptin downregulated the expression of RIP3 in diabetic
hearts
Compared with controls, diabetic myocardial tissues showed
increased number of RIP3-positive particles distributed around the
nucleus, which were decreased in number with sitagliptin treat-
ment (Fig. 7.1). The mRNA and protein levels of RIP3 were increased
in diabetic myocardial tissues (P < 0.01e0.05) and were decreased
with sitagliptin treatment (P < 0.01e0.05).
3.11. Sitagliptin inhibits myocardial apoptosis
Diabetic rats showed irregular myocardial nuclei, nuclear pyk-
nosis, chromatin aggregation, early presentation of apoptotic cells,
with clear myocardial cellular nucleolus, smooth and complete
nuclear membrane in controls and no obvious aggregation of
Fig. 6. (continued).
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sitagliptin treatment smoothed the nuclear membrane in diabetic
rats (Fig. 7.2). Compared with controls, diabetic rats showed
increased proportion of apoptotic cells (P < 0.01), which was
decreased with sitagliptin treatment (P < 0.01). With the correla-
tion between the RIP3 mRNA and cellular apoptotic rate in diabetic
myocardial tissues (Pearson r ¼ 0.795, P < 0.001), the positive
percentage of apoptosis was related to RIP3 mRNA in diabetic
myocardial tissues.
4. Discussion
Sitagliptin, a DPP-Ⅳ inhibitor, has a biological role in
improving the serum levels of GLP-1. GLP-1 reduces hypergly-
cemia but may also trigger direct effects on the heart (20). We
sought to determine the effect of sitagliptin on myocardialinﬂammation, collagen metabolism, lipid content and myocardial
apoptosis in diabetic rats. Sitagliptin improved metabolic
disturbance, reversed myocardial remodeling and lipid accumu-
lation, inhibited cardiac inﬂammation, reduced collagen synthe-
sis, and minimized apoptotic cells in STZ-induced diabetic rat
hearts. RIP3 was overexpressed and positively correlated with
number of apoptotic cells in diabetic myocardial tissues; sita-
gliptin downregulated the expression and minimized the num-
ber of apoptotic cells. Sitagliptin could improve the systolic and
diastolic functions of the left ventricle in diabetic rats by
reducing the E/E0 ratio, promoting LVSP and decreasing LVEDP,
±dp/dt max and Tau. It reversed the altered blood glucose, HbA1
and lipid levels, and plasma GLP-1 and insulin levels, and
reduced fat deposition in diabetic myocardial and epicardial
tissues, so sitagliptin may play an essential role in improving
diabetic cardiac dysfunction and cardiomyopathy.
Fig. 6. (continued).
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diomyopathy (1,2,16,21), and is closely related to fat deposition. Ti
et al. (16) reported that TNF-a and IL-6 were overexpressed in
diabetic rats. Biomarkers of inﬂammation including TNF-a and IL-6
levels are associated with risk of developing type 2 diabetes.
Consistent with these reports, our results showed an increase in
TNF-a and IL-6 levels in diabetic myocardial tissues as well as fat
deposition in diabetic myocardial and epicardial tissues. However,
sitagliptin could reduce the expression of TNF-a and IL-6 and fat
deposition in the diabetic heart, so sitagliptin might lower the
morbidity and mortality of diabetic complications associated with
inﬂammation (22,23).Previous studies (1,2,16) have demonstrated that myocardial
ﬁbrosis is a typical characteristic of diabetic cardiomyopathy.
Both the deposition and disordered arrangement of type I and/or
Ⅲ collagen and abnormal expression of MMPs/TIMPs, and cyto-
kines TGF-b1 or insulin-like growth factor 1 contribute to the
development of myocardial ﬁbrosis and cardiac diastolic
dysfunction. However, some reports (24,25) demonstrated that a
GLP-1R agonist can inhibit the expression of TGF-b1. However,
this study found that sitagliptin reduced aberrant interstitial and
perivascular collagen accumulation, as well as total collagen
content. Echocardiography and catheterization results revealed
that the LV diastolic dysfunction improved, which was attributed
Fig. 7. Sitagliptin reduced the expression of RIP3 and inhibited myocardial apoptosis. Sitagliptin reduced the expression of 7.1(AeC): RIP3; 7.2(AeB): inhibited myocardial apoptosis;
and 7.2(C): proportion of myocardial apoptotic cells positively correlated with relative levels of RIP3 mRNA (Data are mean ± SEM; Compared with control, *P ＜ 0.05, **P＜ 0.01;
Compared with DPP-Ⅳi (High), #P ＜ 0.05, ##P ＜ 0.01; Compared with DPP-Ⅳi (Low), xP ＜ 0.05, xxP ＜ 0.01.).
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and MMP-1 and -9 expression. Thus, sitagliptin improved LV
diastolic dysfunction in diabetic rats by attenuating myocardial
ﬁbrosis.
In addition to the above changes, diabetic myocardial tissues
show apoptosis and necrosis of myocardiocytes. Recent reports
(26e29) demonstrated that GLP-1 could play a key role in the
progress of inhibiting apoptosis during I/R injury. In contrast, gli-
benclamide exacerbates I/R injury and deteriorates cardiac func-
tion (30,31). A GLP-1R agonist enhanced b-cell proliferation and
neogenesis in STZ-treated rats and reduced b-cell apoptosis in part
via endoplasmic reticulum stress (32,33). DeNicola et al. (34)
found that GLP-1R served as a novel approach to eliciting car-
dioprotection and mitigating oxidative stress-induced injury.
Consistent with these reports, our results show that sitagliptin
minimized the number of apoptotic cells and RIP3 wasoverexpressed and correlated positively with the number of
apoptotic cells in the diabetic rat heart; furthermore, sitagliptin
downregulated the expression of RIP3 and minimized the number
of apoptotic cells. Attenuating cardiac apoptosis might be due to
downregulated RIP3 after administration of sitagliptin. Thereafter,
sitagliptin improved LV systolic dysfunction. An GLP-1 analog
protected cardiomyocytes against high glucose-induced apoptosis
by activating the Epac-1/Akt pathway (35). However, the exact
mechanism of sitagliptin reversing these changes and the signal
pathway remains unknown.
In summary, our study is a ﬁrst step in unifying many factors in
the diabetogenic processes in a relevant in vivo system and in-
vestigates sitagliptin as a DPP-Ⅳ inhibitor for the diabetic heart to
help move us closer to ﬁnding effective treatment or prevention
strategies. Future study could investigate difference doses of
sitagliptin.
Fig. 7. (continued).
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